CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Long-Term Clinical Benefit of Sirolimus-Eluting Stents in Patients With In-Stent RestenosisResults of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) Study
Fernando Alfonso, MD*,*,
María-José Pérez-Vizcayno, MD*,
Rosana Hernández, MD*,
Armando Bethencourt, MD ,
Vicens Martí, MD ,
José R. López-Mínguez, MD ,
Juan Angel, MD||,
Andrés Iñiguez, MD¶,
César Morís, MD#,
Angel Cequier, MD**,
Manel Sabaté, MD ,
Javier Escaned, MD*,
Pilar Jiménez-Quevedo, MD*,
Camino Bañuelos, MD*,
Alfonso Suárez, MD*,
Carlos Macaya, MD* for the RIBS-II Investigators
* University Hospital, Clinico San Carlos, Madrid, Spain
University Hospital, Son Dureta, Palma de Mallorca, Spain
University Hospital, San Pablo, Barcelona, Spain
University Hospital, Infanta Cristina, Badajoz, Spain
|| University Hospital, Valle de Hebrón, Barcelona, Spain
¶ University Hospital, Meixoeiro, Vigo, Spain
# University Hospital, Central Asturias, Oviedo, Spain
** University Hospital, Bellvitge, Barcelona, Spain
Manuscript received June 12, 2008;
revised manuscript received August 11, 2008,
accepted August 19, 2008.
* Reprint requests and correspondence: Dr. Fernando Alfonso, Cardiología Intervencionista, Instituto Cardiovascular, Hospital Universitario "San Carlos," Ciudad Universitaria, Plaza de Cristo Rey, Madrid 28040 Spain (Email: falf{at}hotmail.com).
Objectives: We sought to assess the long-term effectiveness and safety of sirolimus-eluting stents (SES) in patients with in-stent restenosis (ISR).
Background: Treatment of patients with ISR remains a challenge. The long-term outcome of patients with ISR treated with SES remains unknown.
Methods: The RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study was a randomized trial conducted in 150 patients with ISR (76 SES, 74 balloon angioplasty [BA]). The long-term (>1 year) clinical outcome and pre-specified subgroup analyses were pre-defined secondary study end points.
Results: At 1 year, the event-free survival (death, myocardial infarction, target vessel revascularization [TVR]) was better in the SES group (88% vs. 69%, p < 0.005). Additional long-term (>3 years) clinical follow-up was obtained in 97% of patients (median 3.3 years). After the first year, 3 patients died (1 SES, 2 BA), 5 suffered myocardial infarction (4 SES, 1 BA), and 7 required TVR (4 SES, 3 BA). At last follow-up, definitive/probable/possible stent thrombosis was similar in both groups (2/2/1 SES vs. 1/0/3 BA, p = NS). At 4 years, the event-free survival was 76% in the SES arm and 65% in the BA arm (p = 0.019). On multivariate analysis, SES implantation was an independent predictor of event-free survival. Subgroup analyses were consistent with the main outcome measure.
Conclusions: In patients with ISR, SES implantation remains effective and safe at very long-term clinical follow-up.
Key Words: angiography angioplasty restenosis sirolimus-eluting stents
|
Abbreviations and Acronyms
| | BA = balloon angioplasty | | CI = confidence interval | | DES = drug-eluting stent(s) | | HR = hazard ratio | | ISR = in-stent restenosis | | MI = myocardial infarction | | SES = sirolimus-eluting stent(s) | | TVR = target vessel revascularization |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A28.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
M. Zangari, L. M. Fink, F. Elice, F. Zhan, D. M. Adcock, and G. J. Tricot
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
J. Clin. Oncol.,
October 10, 2009;
27(29):
4865 - 4873.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol.,
June 2, 2009;
53(22):
2080 - 2097.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008.
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
373 - 398.
[Full Text]
[PDF]
|
 |
|
|